Cookie policy

This cookie policy (“Policy”) describes what cookies are and how and they’re being used by the clinicalpathways.io website (“Website” or “Service”) and any of its related products and services (collectively, “Services”). This Policy is a legally binding agreement between you (“User”, “you” or “your”) and Dr QuickNotes LTD (“Dr QuickNotes LTD”, “we”, “us” or “our”). You should read this Policy so you can understand the types of cookies we use, the information we collect using cookies and how that information is used. It also describes the choices available to you regarding accepting or declining the use of cookies. For further information on how we use, store and keep your personal data secure, see our Privacy Policy.

What are cookies?

Cookies are small pieces of data stored in text files that are saved on your computer or other devices when websites are loaded in a browser. They are widely used to remember you and your preferences, either for a single visit (through a “session cookie”) or for multiple repeat visits (using a “persistent cookie”).

Session cookies are temporary cookies that are used during the course of your visit to the Website, and they expire when you close the web browser.

Persistent cookies are used to remember your preferences within our Website and remain on your desktop or mobile device even after you close your browser or restart your computer. They ensure a consistent and efficient experience for you while visiting the Website and Services.

Cookies may be set by the Website (“first-party cookies”), or by third parties, such as those who serve content or provide advertising or analytics services on the Website (“third party cookies”). These third parties can recognize you when you visit our website and also when you visit certain other websites.

What type of cookies do we use?

Necessary cookies

Necessary cookies allow us to offer you the best possible experience when accessing and navigating through our Website and using its features. For example, these cookies let us recognize that you have created an account and have logged into that account to access the content.

Functionality cookies

Functionality cookies let us operate the Website and Services in accordance with the choices you make. For example, we will recognize your username and remember how you customized the Website and Services during future visits.

Analytical cookies

These cookies enable us and third party services to collect aggregated data for statistical purposes on how our visitors use the Website. These cookies do not contain personal information such as names and email addresses and are used to help us improve your user experience of the Website.

What are your cookie options?

If you don’t like the idea of cookies or certain types of cookies, you can change your browser’s settings to delete cookies that have already been set and to not accept new cookies. To learn more about how to do this or to learn more about cookies, visit internetcookies.org

Please note, however, that if you delete cookies or do not accept them, you might not be able to use all of the features the Website and Services offer.

Changes and amendments

We reserve the right to modify this Policy or its terms relating to the Website and Services at any time, effective upon posting of an updated version of this Policy on the Website. When we do, we will revise the updated date at the bottom of this page. Continued use of the Website and Services after any such changes shall constitute your consent to such changes.

Acceptance of this policy

You acknowledge that you have read this Policy and agree to all its terms and conditions. By accessing and using the Website and Services you agree to be bound by this Policy. If you do not agree to abide by the terms of this Policy, you are not authorized to access or use the Website and Services.

Contacting us

If you would like to contact us to understand more about this Policy or wish to contact us concerning any matter relating to our use of cookies, you may send an email to support@productivemedic.com

This document was last updated on December 30, 2020

error: Alert: Content is protected !!

SVG pop-op

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Considerations for Prescribing SGLT2i Therapy in Type 2 Diabetes Mellitus

The clinical summary below aims to offer practical advice for healthcare professionals when prescribing SGLT2i therapies for the treatment of T2DM. Please refer to the relevant individual SmPC before prescribing any SGLT2i therapy: Canagliflozin | Dapagliflozin | Empagliflozin | Ertugliflozin

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Canagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = 100mg, titrate → 300mg if required | 45 - 59 = Use 100mg only | < 45 = not recommended for glycaemic control
Indication: T2D + Diabetic Kidney Disease
↓eGFR: ≥ 30 = Initiate and continue 100mg | < 30* = Continue but do not initiate 100mg | Dialysis = STOP
*With urinary albumin/creatinine ratio > 30 mg/mol

SOURCE: @Visualmedapp

Empagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 45 - 60 = Continue 10mg only but do not initiate | < 45 = STOP
Indication: T2D AND estalished cardiovascular disease
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 30 - 60 = Initiate or continue 10mg only | < 30 = STOP
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 20 = Initiate or continue 10mg | < 20 = STOP

SOURCE: @Visualmedapp

Ertugliflozin | Dose | Safety | Side-effects | NICE
↓eGFR: Initiate only if eGFR ≥ 60 = 5mg, titrate → 15mg if required | < 45 = STOP

SOURCE: @Visualmedapp

Empagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 45 - 60 = Continue 10mg only but do not initiate | < 45 = STOP
Indication: T2D AND estalished cardiovascular disease
↓eGFR: ≥ 60 = Initiate 10mg, titrate → 25mg if required | 30 - 60 = Initiate or continue 10mg only | < 30 = STOP
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 20 = Initiate or continue 10mg | < 20 = STOP

SOURCE: @Visualmedapp

Dapagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 45 = 10mg| < 45 = not recommended for glycaemic control
Indication: Chronic HFrEF with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate
Indication: Chronic Kidney Disease with or without T2D
↓eGFR: ≥ 15 = 10mg| < 15 = Continue but don't initiate

SOURCE: @Visualmedapp

Canagliflozin | Dose | Safety | Side-effects | NICE
Indication: T2D glycaemic control
↓eGFR: ≥ 60 = 100mg, titrate → 300mg if required | 45 - 59 = Use 100mg only | < 45 = not recommended for glycaemic control
Indication: T2D + Diabetic Kidney Disease
↓eGFR: ≥ 30 = Initiate and continue 100mg | < 30* = Continue but do not initiate 100mg | Dialysis = STOP
*With urinary albumin/creatinine ratio > 30 mg/mol

SOURCE: @Visualmedapp